Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.50 |
| ▸ | ADH1C | P00326 | 1/20 | 0.50 |
| ▸ | ADH1A | P07327 | 1/20 | 0.50 |
| ▸ | ADH4 | P08319 | 1/20 | 0.50 |
| ▸ | ADH7 | P40394 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 8/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23519562 | 1.00 | ADH1B (0.50) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL17104353 | 0.97 | ADH1B (0.54) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL10066725 | 0.97 | ADH1B (0.54) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL2310099 | 0.97 | ADH1B (0.54) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL15534730 | 0.97 | ADH1B (0.54) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL9204901 | 0.97 | ADH1B (0.54) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL7762311 | 0.97 | ADH1B (0.54) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL2360620 | 0.97 | ADH1B (0.54) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL3146350 | 0.97 | ADH1B (0.54) | ADH1BADH1CADH1AADH4ADH7 | |
| Hydrochloric Acid SCHEMBL28535575 | 0.97 | ADH1B (0.48) | ADH1BADH1CADH1AADH4ADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117510500-A | Preparation method of asperazepanones alkaloid and application of asperazepanones alkaloid as anti-inflammatory drug | 中国海洋大学 | 2024-02-06 | — | — | CN | disclosed |
| CN-117050043-A | 3-phenyl dibenzofuran compound and preparation method and application thereof | 中国海洋大学 | 2023-11-14 | — | — | CN | disclosed |
| CN-116802184-A | Pyrazolothiazole carboxamides and their use as PDGFR inhibitors | 埃科特莱茵药品有限公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-116726010-A | Application of macrolide derivative in preparation of medicines for inhibiting pro-inflammatory cytokine acting agents | 中国海洋大学 | 2023-09-12 | — | — | CN | disclosed |
| CN-112851622-B | Macrolide brefeldin A ester derivative and application thereof | 中国海洋大学 | 2023-01-10 | — | — | CN | disclosed |
| EP-3049114-B1 | CARRIER-FREE BIOLOGICALLY-ACTIVE PROTEIN NANOSTRUCTURES | MASSACHUSETTS INST TECHNOLOGY (US) | 2021-11-10 | — | — | EP | disclosed |
| CN-112851622-A | Macrolide brefeldin A ester derivative and application thereof | 中国海洋大学 | 2021-05-28 | — | — | CN | disclosed |
| EP-3825320-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING ORGANOMETALLIC COMPOUND | Samsung Electronics Co., Ltd. (KR) | 2021-05-26 | — | — | EP | disclosed |
| US-20170239352-A1 | COMBINATION DRUG THERAPY FOR THE TREATMENT OF SOLID TUMORS | UNIV DUKE (US) | 2017-08-24 | — | — | US | disclosed |
| US-8017670-B2 | Epoxy resin composition for optical-semiconductor encapsulation, cured resin thereof, and optical semiconductor device obtained with the same | NITTO DENKO CORPORATION (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20070027147-A1 | Biarylurea derivatives | MSD K.K. (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20030158237-A1 | Combination of antioxidant substances for the treatment of alzheimer's disease | COLBA R & D INC. (CA) | 2003-08-21 | — | — | US | disclosed |
| EP-1290002-A1 | CHEMICAL PRODUCTS SUITED FOR USE AS CO-CATALYSTS, METHOD FOR THE PREPARATION THEREOF AND THEIR USE IN CATALYST SYSTEMS FOR PRODUCING POLYOLEFINS | Basell Polyolefine GmbH (DE) | 2003-03-12 | — | — | EP | disclosed |
| EP-1280600-A2 | SUPPORTED CATALYST SYSTEM COMPRISING A METALLOCENE, A LEWIS-BASE AND AN ORGANODEMENTAL COMPOUND OF MAIN GROUP III, AND ITS USE | Basell Polypropylen GmbH (DE) | 2003-02-05 | — | — | EP | disclosed |
| EP-1250363-A2 | CHEMICAL COMPOUND, METHOD FOR THE PRODUCTION THEREOF AND ITS USE IN CATALYST SYSTEMS FOR PRODUCING POLYOLEFINS | Basell Polyolefine GmbH (DE) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001090112-A1 | CHEMICAL PRODUCTS SUITED FOR USE AS CO-CATALYSTS, METHOD FOR THE PREPARATION THEREOF AND THEIR USE IN CATALYST SYSTEMS FOR PRODUCING POLYOLEFINS | BASELL POLYOLEFINE GMBH (DE) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001047635-A2 | SUPPORTED CATALYST SYSTEM CONTAINING A METALLOCENE, A LEWIS BASE AND AN ELEMENTALLY ORGANIC COMPOUND OF MAIN GROUP III AND THE USE THEREOF | BASELL POLYPROPYLEN GMBH (DE) | 2001-07-05 | — | — | WO | disclosed |
| WO-2001048035-A2 | CHEMICAL COMPOUND, METHOD FOR THE PRODUCTION THEREOF AND ITS USE IN CATALYST SYSTEMS FOR PRODUCING POLYOLEFINS | BASELL POLYOLEFINE GMBH (DE) | 2001-07-05 | — | — | WO | disclosed |
| EP-0361230-A2 | Mixtures from polyamides, aromatic polycarbonates and maleic imide copolymeres and use of them as thermoplastic moulding compositions | BAYER AG (DE) | 1990-04-04 | — | — | EP | disclosed |
| US-4906634-A | Novel N-[4-(aminosubstituted)phenyl]methanesulfonamides and their use as cardiovascular agents | SCHERING A.G. (DE) | 1990-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027147-A1 | Biarylurea derivatives | CDK6, CDK4, CCNI | ADH1B 818/4885ADH1C 2863/4885ADH1A 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.